Discordance between Genexpert, Line Probe Assay and Drug Susceptibility Test in Assessing Drug-Resistant Tuberculosis
Keywords:Rapid test, conventional culture, drug susceptibility test, line probe assay, drug-resistant tuberculosis
Background: Rapid molecular diagnostics have potentially revolutionized early detection of drug-resistant
tuberculosis (DR-TB) in Indonesia. However, there is discordance between conventional culture using
drug susceptibility test (DST) and rapid diagnostic tools using GeneXpert and line probe assay (LPA).
This discordance result can cause confusion to clinician in determining diagnosis of DR-TB. Objective:
This study aimed to identify discordance between GeneXpert, LPA, and DST. Methods: A retrospective
study was conducted at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Data were collected
based on medical record between third to fourth quarter of 2018. Rifampicin resistant-tuberculosis (RR-TB)
proven by GeneXpert, were further analyzed with second-line LPA and DST. Discordance result between
it was analyzed using McNemar. Results: Among 81 patients diagnosed with DR-TB, 59 patients RR-TB
were eligible in this study. There were 13 (22.0%) DST rifampicin result showed sensitive but resistant
to GeneXpert. Among 53 samples from LPA, there were 3 (5.7%) result showed LPA fluoroquinolone
resistant but sensitive to DST ofloxacin; 10 (18.9%) result has LPA fluoroquinolone sensitive but resistant
to DST ofloxacin; 2 (3.8%) has LPA second-line injectable drug (LPA SLID) resistant but sensitive to DST
kanamycin; 5(9.4%) has LPA SLID sensitive but resistant to DST kanamycin. The McNemar analysis showed
discordance between GeneXpert and DST rifampicin was 13 (22.0%; p=0.046); LPA fluoroquinolone and
DST ofloxacin was 13 (24.6%; p=0.042); LPA SLID and DST kanamycin was 7 (13.2%; p=0.183). No
variable that can be used to analyze discordance result between GeneXpert and LPA. Conclusion: There
is significant discordance between GeneXpert and DST; LPA fluoroquinolone and DST ofloxacin, while
neither LPA SLID nor DST kanamycin shows no significant discordance.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions